Double-J (DJ) stents, commonly used to relieve ureteral obstructions, often cause lower urinary tract symptoms (LUTS) such as pain, haematuria, and urinary tract infections, significantly impacting patients’ quality of life. These symptoms primarily result from bladder irritation and ureteral spasms caused by the stent’s positioning and movement. While alpha-blockers like tamsulosin and anticholinergics like solifenacin have shown effectiveness in managing these symptoms, the role of beta-3 agonists, such as mirabegron, is less explored despite it’s success in treating overactive bladder (OAB). With limited research comparing the efficacy of these medications for DJ stent-related LUTS, there is a critical need for further studies to address this gap and identify optimal treatment strategies to enhance patient care.

Hypothesis: Compared to other medications, mirabegron shows comparable results on LUTS and performs better on overactive bladder symptoms due to DJ stents. Tamsulosin shows similar results to that of Mirabegron, and there is no additional benefit of using the combination.